Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

CC-11050 Trial in Nepalese Patients With Erythema Nodosum Leprosum

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03807362
Recruitment Status : Recruiting
First Posted : January 16, 2019
Last Update Posted : January 16, 2019
Sponsor:
Information provided by (Responsible Party):
The Leprosy Mission Nepal

Brief Summary:
This study will be a single center, Phase 2, open-label trial to evaluate the safety and efficacy of 200mg CC-11050 administered twice daily taken with food for patients with moderate to severe ENL. The study will be performed in two steps: 1) to evaluate immediate effect in safety and efficacy of drug in 10 males with new or new recurrent episode ENL and, if found to be safe and effective by the DSMB and 2) if allowed by the DSMB, and approved by relevant study stakeholders, an additional 40 ENL patients will be enrolled for up to 52 weeks of treatment. A safety analysis will be conducted on all patients who have received at least one dose of study drug, and will include the frequency of all adverse events and laboratory abnormalities as well as frequency of dose interruptions, dose reductions and treatment discontinuation.

Condition or disease Intervention/treatment Phase
Erythema Nodosum Leprosum Leprosy Drug: CC-11050 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Intervention Model: Single Group Assignment
Intervention Model Description: A single center, open label pilot study
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single Center, Open Label Pilot Study to Evaluate the Safety and Efficacy of CC-11050 in Nepalese Patients With Erythema Nodosum Leprosum
Actual Study Start Date : January 7, 2018
Estimated Primary Completion Date : March 30, 2021
Estimated Study Completion Date : December 31, 2024

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: CC-11050 treatment
200mg CC-11050 will be administered twice daily as a pill taken with food (at breakfast and evening meal) for participants with moderate to severe ENL for 10 days, then up to 28 days (during Step 1) and then up to 1 year (during Step 2).
Drug: CC-11050
CC-11050 is a novel anti-inflammatory compound with potential to treat a variety of chronic inflammatory conditions.




Primary Outcome Measures :
  1. Number of participants with moderate to severe ENL with severity changes as assessed by the ENL Severity Scale. [ Time Frame: 10 days, 28 days and monthly up to 1 year of treatment ]
    Changes in ENL Severity Scale Score (Walker et al., PLoS Negl Trop Dis 11(7): e0005716, https://doi.org/10.1371/journal.pntd.0005716) as compared to baseline and any previous time points. Ten clinical categories contribute 0-3 points toward the total score of 0-30. An ENL patient with a total scale score of less than 9 is considered to have mild ENL, while scores >9 are considered moderate to severe ENL. A minimum score of 9 is required to indicate sufficient ENL symptoms from which post-intervention reduction in score(s) can be determined meaningful improvement.


Secondary Outcome Measures :
  1. Number of participants with moderate to severe ENL with decreased duration of episode(s) as assessed by standard ENL episode definition. [ Time Frame: 10 days, 28 days, monthly up to 1 year of treatment and up to 1 year followup after treatment cessation. ]
    Changes in ENL episode duration(s) as compared to baseline and any previous time points. By definition, if ENL symptoms are separated by time and no need of treatment for >28 days, they are considered separate episodes. Recurrence is anytime another episode occurs after >28 days of no prior treatment or symptoms.

  2. Number of participants with moderate to severe ENL with decreased bacterial index (BI) as assessed by slit skin smear microscopy. [ Time Frame: Enrolment and after 1 year treatment. ]
    Changes in slit skin smear microscopy BI as compared to baseline. BI can range from 0-6.

  3. Number of participants with moderate to severe ENL with decreased bacterial index (BI) as assessed skin histopathology. [ Time Frame: Enrolment and after 1 year treatment. ]
    Changes in skin histopathology bacterial index (BI) as compared to baseline. BI can range from 0-6.

  4. Number of patients with moderate to severe ENL with improved peripheral neuropathy as assessed by standardized monofilament and voluntary muscle tests. [ Time Frame: enrolment, 10 days, 28 days, biweekly (as needed), up to 1 year treatment, up to 1 year followup after treatment cessation ]
    Changes in scores for peripheral neuropathy as indicated by monofilament and voluntary muscle tests compared from baseline and any previous time points. To check neuropathy, 7 motor function nerves and 6 sensory function nerves on each side of the body are assessed for a total 26 nerves. Each are assessed on 3 sites using a standard set of Semmes-Weinstein monofilaments. The 200mg filament and the 2g filament represent threshold for the hand and foot, respectively. The 0-5 Medical Research Council (MRC) scale is used for motor function assessment. Sensory scores >3 and motor nerve scoring (MRC) < 5 are regarded impaired (indicating neuropathy). More method specifics can be found here: van Veen N.H., et al., Corticosteroids for treating nerve damage in leprosy. Cochrane Database Syst Rev, 2007(2): p. CD005491.

  5. Number of participants with moderate to severe ENL with improved quality of life as assessed by the World Health Organization Quality of Life tool. [ Time Frame: Enrolment, 28 days, monthly up to 1 year of treatment and up to 1 year followup after treatment cessation. ]
    Changes in scores for the World Health Organization Quality of Life assessment as compared to baseline and any previous time points. There are 26 questions in this questionnaire and each can be scored from 1 to 5 points. The highest possible score is 130 and lowest possible score is 26. A higher score denotes better quality of life.

  6. Number of participants with moderate to severe ENL as assessed by standard blood panel and basic metabolic testing. [ Time Frame: Enrolment, day 10, day 17, day 28, monthly up to 1 year of treatment, and 1 month post-cessation of treatment. ]
    Abnormalities or change in values in comparison to baseline and any previous time points.

  7. Number of participants with moderate to severe ENL as assessed by urinalysis. [ Time Frame: Enrolment, day 10, day 17, day 28, monthly up to 1 year of treatment, and 1 month post-cessation of treatment. ]
    Detection of albumin (qualitative) as compared to baseline and any previous time points. Urine albumin is related to ENL severity and kidney function test.

  8. Number of participants with moderate to severe ENL as assessed by serological indicators associated with ENL. [ Time Frame: Enrolment, day 10, day 17, day 28, monthly up to 1 year of treatment, and 1 month post-cessation of treatment. ]
    Detection of rheumatoid arthritis factor (positive) and/or C-reactive protein (positive) as compared to baseline and any previous time points.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Males only for Step 1 (first 10 patients for testing up to 28 days of treatment). If successful, then both males and females can enroll in the second part of the study (up to 40 patients testing up to 1 year of therapy).
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Study participants must satisfy the following criteria to be enrolled in the study:

  1. Must be 18 -65 years old, weight > 35kg for women and >40kg for men at the time of signing the informed consent.
  2. Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures are conducted.
  3. Have signs or symptoms of new or new episode ENL. In Step one, participants must be male. In Step 2, participants can be either male or female.
  4. Able to adhere to the study schedule and other protocol requirements.

Exclusion Criteria:

The presence of any of the following will exclude a participant from enrollment:

  1. Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the participants from participating in the study.
  2. Patients on continuous rifampicin will be excluded, however, If rifampicin is given only once a month as part of a multi-drug regimen, a minimum of 2-week washout period is required prior to administration of CC-11050
  3. Any condition including the presence of laboratory abnormalities, which places the participant at unacceptable risk if he were to participate in the study.
  4. Any condition that confounds the ability to interpret data from the study (ie, HIV, chronic HepB, chronic HepC or TB patients under active treatment). Resolved TB patients will not be excluded from the study.
  5. Stable and well managed patients with Diabetes and hypertension will not be excluded from the study.
  6. Use of systemic corticosteroid or immunosuppressant therapy within 7 days of study medication initiation
  7. Pregnant or nursing females.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03807362


Contacts
Layout table for location contacts
Contact: Mahesh Shah, MD +9779841203417 drmahesh_shah@yahoo.com
Contact: Indra B Napit, MD indranapit@yahoo.com

Locations
Layout table for location information
Nepal
The Leprosy Mission Nepal Not yet recruiting
Kathmandu, Bagmati, Nepal, 44700
Contact: Mahesh Shah, MD       drmahesh_shah@yahoo.com   
Contact: iIndra B Napit, MD       indran@tlmnepal.org   
Anandaban Hospital Recruiting
Lalitpur, Bagmati, Nepal, 44700
Contact: Indra B Napit, MD    +9779851136027    indran@tlmnepal.org   
Contact: Mahesh Shah, MD    +9779841203417    drmahesh_shah@yahoo.com   
Sub-Investigator: Deanna A Hagge, PhD         
Sponsors and Collaborators
The Leprosy Mission Nepal
Investigators
Layout table for investigator information
Principal Investigator: Mahesh Shah, MD The Leprosy Mission Nepal

Layout table for additonal information
Responsible Party: The Leprosy Mission Nepal
ClinicalTrials.gov Identifier: NCT03807362     History of Changes
Other Study ID Numbers: Nepal CC-11050
First Posted: January 16, 2019    Key Record Dates
Last Update Posted: January 16, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Erythema
Leprosy
Erythema Nodosum
Skin Diseases
Skin Manifestations
Signs and Symptoms
Mycobacterium Infections
Actinomycetales Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Drug Eruptions
Dermatitis
Drug Hypersensitivity
Hypersensitivity
Immune System Diseases
Drug-Related Side Effects and Adverse Reactions
Chemically-Induced Disorders